Related Experiment Video

Updated: Sep 3, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K

Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines

Carlos A Gongora1, Zsofia D Drobni2, Thiago Quinaglia Araujo Costa Silva3

  • 1Cardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

JACC. Heart Failure
|July 28, 2022
PubMed
Abstract

Insights

Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduced cardiac events and mortality in cancer patients receiving anthracyclines. This study suggests SGLT2 inhibitors are safe and effective in this high-risk population.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Sodium-glucose co-transporter-2 (SGLT2) inhibitors are known to improve heart failure outcomes.
  • Limited data exist on SGLT2 inhibitor efficacy in patients treated with anthracyclines.

Purpose of the Study:

  • To evaluate the cardiac efficacy of SGLT2 inhibitors in patients receiving anthracyclines.
  • To assess the overall safety of SGLT2 inhibitors in this patient cohort.

Main Methods:

  • Retrospective study of 3,033 patients with diabetes mellitus and cancer treated with anthracyclines.
  • Case group (n=32) received SGLT2 inhibitors during anthracycline treatment; control group (n=96) did not.
  • Primary outcomes: composite cardiac events and overall mortality.

Main Results:

  • SGLT2 inhibitor use was associated with a significantly lower incidence of cardiac events (3% vs. 20%, P=0.025).
  • Overall mortality was substantially lower in the SGLT2 inhibitor group (9% vs. 43%, P<0.001).
  • SGLT2 inhibitors also reduced sepsis and neutropenic fever composite outcomes (16% vs. 40%, P=0.013).

Conclusions:

  • SGLT2 inhibitors demonstrate significant cardiac benefits in patients with cancer and diabetes mellitus undergoing anthracycline therapy.
  • The findings support the use of SGLT2 inhibitors as a potentially safe and effective treatment in this high-risk population.
  • A randomized clinical trial is warranted to confirm these promising results.
Keywords:
SGLT2 inhibitorsanthracycline-induced cardiomyopathycardiotoxicitycardiovascular outcomeschemotherapy doxorubicinheart failure

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
277
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
247
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
704
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
241
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
122.9K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.0K